|Bid||0.3800 x 800|
|Ask||0.5290 x 900|
|Day's Range||0.4947 - 0.5299|
|52 Week Range||0.2800 - 1.2500|
|Beta (3Y Monthly)||4.87|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.67|
Genocea Biosciences, Inc. (GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it has entered into a private placement with certain existing and new investors providing for the purchase of up to approximately $39.2 million of its common stock and warrants to purchase shares of Genocea common stock, in two closings. In the first closing, Genocea will offer 25.6 million shares of common stock and 4.25 million pre-funded warrants to purchase common stock, along with accompanying warrants to purchase 0.25 shares of common stock for each share of common stock or pre-funded warrant purchased by an investor, for expected aggregate gross proceeds to Genocea of approximately $15.0 million (before deducting fees to the placement agents and other offering expenses payable by Genocea).
Anyone researching Genocea Biosciences, Inc. (NASDAQ:GNCA) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and there Read More...
CORAL GABLES, FL / ACCESSWIRE / January 2, 2019 / With the new year only a few days old, the healthcare sector is already showing signs that this year may prove exciting for the market. From data-based approaches and analysis consumer demands/needs, advancements in the sector may catalyze potential opportunities for those looking to healthcare. Premier Health Group (PHGRF) (PHGI), Regional Health Properties, Inc (NYSE: RHE), Genocea Biosciences Inc (NASDAQ: GNCA), and Synergy Pharmaceutical, Inc (NASDAQ: SGYP) are 4 healthcare stocks heating up on Wednesday.
Genocea Biosciences, Inc. (GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced the dosing of the first patients in its Phase 1/2a clinical trial testing the safety, immunogenicity, and clinical efficacy of its neoantigen cancer vaccine candidate GEN-009. Genocea also announced that enrollment of patients in the first part of the clinical trial has been completed. Unlike machine-based approaches that predict neoantigens and only evaluate the patient’s tumor, ATLAS also uses each patient’s own immune cells not only to identify true neoantigens that already trigger anti-tumor cytokine responses, but also to eliminate “inhibitory” antigens that are frequently selected for vaccine inclusion by such in silico approaches.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices Read More...
CAMBRIDGE, Mass., Dec. 10, 2018 -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced the.
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
The Cambridge, Massachusetts-based company said it had a loss of 9 cents per share. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
A look at the shareholders of Genocea Biosciences Inc (NASDAQ:GNCA) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, Read More...
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 5 cents. Losses, adjusted for non-recurring gains, were 11 cents per share. The results topped Wall Street expectations. ...
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Genocea Biosciences, Inc. (NASDAQ: GNCA ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 9:00 AM Eastern ...